Pacific Biosciences Of California (PACB) Income from Continuing Operations (2010 - 2026)

Pacific Biosciences Of California's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 8275000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 98.06% year-over-year to 8275000.0 in Q1 2026; TTM through Mar 2026 was 128576000.0, a 80.45% increase from a year earlier, with the FY2025 full-year figure at 546376000.0, down 76.34% from the prior year.
• Income from Continuing Operations grew to 8275000.0 in Q1 2026 per PACB's latest filing, from 40371000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 2371000.0 in Q4 2024 and bottomed at 426075000.0 in Q1 2025.
• The 5-year median for Income from Continuing Operations is 71394000.0 (2022), against an average of 87381470.59.
• Across the five-year window, Income from Continuing Operations soared 102.89% in 2024 and tumbled 1802.7% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 84384000.0 in 2022, then advanced by 2.8% to 82018000.0 in 2023, then surged by 102.89% to 2371000.0 in 2024, then tumbled by 1802.7% to 40371000.0 in 2025, then surged by 79.5% to 8275000.0 in 2026.
• Per Business Quant, the three latest PACB Income from Continuing Operations figures stand at 8275000.0 (Q1 2026), 40371000.0 (Q4 2025), and 38000000.0 (Q3 2025).